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Abstract
Gene expression analysis has become a ubiquitous tool for studying a wide range of human diseases. In a typical analysis we
compare distinct phenotypic groups and attempt to identify genes that are, on average, significantly different between
them. Here we describe an innovative approach to the analysis of gene expression data, one that identifies differences in
expression variance between groups as an informative metric of the group phenotype. We find that genes with different
expression variance profiles are not randomly distributed across cell signaling networks. Genes with low-expression
variance, or higher constraint, are significantly more connected to other network members and tend to function as core
members of signal transduction pathways. Genes with higher expression variance have fewer network connections and also
tend to sit on the periphery of the cell. Using neural stem cells derived from patients suffering from Schizophrenia (SZ),
Parkinson’s disease (PD), and a healthy control group, we find marked differences in expression variance in cell signaling
pathways that shed new light on potential mechanisms associated with these diverse neurological disorders. In particular,
we find that expression variance of core networks in the SZ patient group was considerably constrained, while in contrast
the PD patient group demonstrated much greater variance than expected. One hypothesis is that diminished variance in SZ
patients corresponds to an increased degree of constraint in these pathways and a corresponding reduction in robustness
of the stem cell networks. These results underscore the role that variation plays in biological systems and suggest that
analysis of expression variance is far more important in disease than previously recognized. Furthermore, modeling patterns
of variability in gene expression could fundamentally alter the way in which we think about how cellular networks are
affected by disease processes.
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Introduction
In studying biological systems, we tend to think of groups as being
defined by specific, measurable parameters, and of the important
differences between those groups as being defined by a significant
average difference in those parameters. Much of the language we
use in describing biological systems is based on this bias and we talk
about genes being expressed in a tissue at a particular level, or about
differences in gene expression between groups reflecting the
mechanism driving their phenotypic differences.
This view of biological systems has been extremely useful in that
nearly all of our understanding of biological systems is based on
interpreting average behavior. Variance in this context is only
used as a measure of the significance of those mean differences
(through the use of statistical measures such as a t-test or
ANOVA). Rarely has the variability across a population been
considered in the analysis of transcriptional differences between
populations. Arguably, variance has been largely ignored because
it has been considered solely in the context of experimental
reproducibility, and therefore something that must be reduced.
This was a reasonable bias in the early days of microarrays, but the
robustness and reproducibility of the current generation of array
platforms [1] allows us to look at additional drivers of variance in
gene expression studies. Increasingly there is evidence that
biological sources of variation may play an important role in
determining cellular and organismal phenotypes [2-8], as well as in
helping to explain a wide range of biological phenomena ranging
from reduced penetrance [9,10] to evolutionary fitness [11].
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The direct link between genetics and reduced penetrance,
expression variability and phenotype was elegantly demonstrated
in C. elegans by Raj and colleagues, who showed that variation in
the number of transcripts expressed in any individual cell, as well
as the number of cells expressing the transcript of interest, directly
influenced the development of the worm’s intestine [6]. Mutations
in key developmental transcription factors affected not just the
mean expression of target genes, but also the variance of their
expression levels. Their model proposed a threshold effect of
absolute gene expression on phenotype, where the availability of
the transcripts dictated cell fate. Penetrance of the mutant trait was
therefore determined by quantifiable variance in gene expression
levels.
Variation, in genetic and phenotypic terms, has long been
considered an important component of population fitness and
adaptability. Similarly, one way to interpret the association
between expression variance and phenotype is to consider how
this might play a role in determining phenotype. Consider a
pathway that plays a role in a developmental process or in a cell’s
response to a particular environmental stimulus. If the genes in
that pathway have very low variance, a natural interpretation is
that those genes are themselves highly constrained, and that the
spectrum of potential responses from activation of that pathway is
itself limited.
This interpretation was explored by examining the difference in
gene expression variance in neural stem cells and fibroblasts
derived from patients suffering from Schizophrenia (SZ), patients
suffering from Parkinson’s disease (PD), and healthy donors
(controls). We demonstrate how gene expression variance can be
used as a way to distinguish between phenotypic groups, the way
in which constraint provides information about network topology,
and to provide insight into the mechanisms associated with disease
and normal states.
Of course it should be noted that any analysis of variance must
be carefully considered in light of the methods used to collect and
analyze biological datasets. Variation in biological systems has
long been considered ‘‘noise’’ to be minimized either through
careful experimental design or through the use of data
normalization methods designed to improve comparisons between
individual samples. However variation includes both biological
and experimental (or random) effects and it is the former, rather
than the latter which is important in the current study.
In our analysis, we considered highly-constrained and lowly-
constrained genes, descriptors synonymous with low variance and
high-variance states, respectively. These definitions, in part, helped
to define our hypothesis: that the degree of variation in the
expression of the genes associated with a particular cellular
network is indicative of the plasticity [12] of that network. In this
sense, high variance is associated with increased plasticity and low
variance with diminished plasticity.
Our approach provides important evidence supporting the
hypothesis that variation is an essential feature of biological
systems and one that influences disease phenotype. In particular
we illustrated that patterns of variance in certain key pathways are
not random, but provide a potential mechanistic understanding of
the phenotypic differences that arise in the development and
progression of particular neurological diseases.
Results
Variance is not distributed randomly across signaling
networks
The olfactory neuroepithelium is a continually regenerating
tissue, and stem cells isolated from biopsied material give rise to
neurons and glia in culture [13], and in transplant models in the
rat [14,15]. Patient-derived human olfactory neurosphere-derived
(hONS) cells have been shown to be an informative tissue-specific
system for studying the etiology of human brain disorders like PD
and SZ [16,17]. In a previous study, gene expression data from
these hONS stem cell lines were used to identify disease-specific
cellular alterations by comparing absolute expression profiles of
hONS between donor groups [16]. Here, we use this same data set
to focus instead on patterns of variability as a means to assess how
hONS deviate from the normal population in PD and SZ donors,
and explore the implications that variability may have on these
disease processes.
Tissue biopsies from skin (fibroblasts) or the neuroepithelium of
the nose were obtained from nine Schizophrenia (SZ) and eleven
healthy control donors. Olfactory biopsies were taken from an
additional thirteen donors with Parkinson’s disease (PD) [16].
Adult stem cell lines are grown from olfactory biopsies for several
passages as primary cultures, then moved through a neurosphere
process to enrich for neural stem cells [13]. hONS cells are
monolayer cultures expanded from disaggregated neurospheres
[13,16]. Patient-specific lines were grown from primary olfactory
mucosa biopsies (primary) and hONS from all donor groups,
additionally skin fibroblast cell lines were grown from the SZ
patients and control donors. Genome-wide transcriptional profil-
ing was performed on individual donor lines with replication (see
Material and Methods). Principal component analysis (Figs. 4–6 in
Text S1) shows that the samples clustered by the disease status of
the donors. All donors used in this analysis were male.
Figure 1 presents an outline of our analysis pipeline. We first
examined the genome-wide expression variance distributions
between skin fibroblasts and hONS derived from the same donors
in the control group (Figure 2). Of the 22,184 probes represented
on the Illumina microarray; 14,986 probes were detected in at
least one cell type. To minimize experimental effects in our
analysis, great care was taken to standardize our laboratory
protocols and the assays that were performed. To explore the
potential contributions of experimental noise, we consider a
number of normalization approaches for microarray data and
show that these effects do not contribute to the differences that we
observe.
As a measure of variance, we used the coefficient of variation
(CV) which is computed for each gene by dividing the standard
deviation of its expression measures across a sample population by
its average expression. We designate highly-constrained genes as
those falling below the lower 25th percentile of the genome-wide
CV distribution based on all donors and lowly-constrained genes
as those above the upper 25th percentile; those genes in the range
Author Summary
Genes are a repository of information that provides the
framework for cellular processes, with the flow of
information from gene (DNA) to phenotype via an
intermediate molecule—the messenger RNA. We under-
stand that sequence variations in a gene may lead to
phenotypic variations, but less well understood is how
variation in the information flow itself might also impact
on phenotype. In this study we demonstrated that disease
phenotypes were correlated with expression variance. A
change in expression variance might infer that the genetic
networks representing information flow were less robust—
surprisingly, we found that too little and too much
variance were equally detrimental in the context of
neurological disease.
Expression Variance and Neurological Disease
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between the 25th and 75th percentile we refer to as the ‘‘Mid
Variability’’ gene set. Basing our analysis on CV values protects
against detecting patterns in variability influenced by trends in
absolute expression alone (Text S1).
Normalization procedures are assumed to reduce or stabilize
variance. To assess the impact of normalization on expression
variance, CV distributions were examined using five normaliza-
tion regimes and summarized in Figure 2: i) log2 transformed;
ii) log2 transformed and median normalised in the presence or;
iii) absence of non-detected probes; iv) log2 transformed and
quantile normalized; v) log2 transformed and robust spline
normalization. The distribution of expression values was consistent
across all of the normalization strategies, which most likely reflects
the high level of reproducibility of the raw data. CV was robust to
the normalization strategy used but was most impacted by
background correction or detection thresholds when using median
normalization: this is discussed further in the Text S1, however all
subsequent analyses were run on log2 transformed, quantile
normalized data. Background subtraction was not performed, but
data was thresholded using the Illumina detection scores. While
the absolute numbers of genes in the ‘low’, ‘medium’ and ‘high’
variance categories varied slightly between the normalization
methods, concordance was high (Figure 2B .75% overlap low-
variance genes; .85% overlap high-variance genes) and the
patterns in the underlying data types were highly reproducible
(Figs. 1–3 in Text S1).
Using gene expression data from hONS and skin fibroblasts
isolated from control donors, we next isolated the core attractor
pathways whose differential expression distinguish a normal
hONS stem cell expression phenotype, using the attract method
that we recently developed [18]. Rather than testing individual
genes, attract begins by using an ANOVA based method to test
gene sets defined by KEGG pathways for their ability to
distinguish between phenotypic states. Pathways ranked as
significant are then each decomposed into ‘‘synexpression
groups’’—subsets with expression profiles that are both highly
correlated and informative for distinguishing between phenotypes.
These synexpression groups are then expanded to include genes
with highly correlated profiles from within the original dataset,
producing a collection of ‘‘core pathway modules.’’
The top five attract modules were the MAPK signaling pathway,
the focal adhesion pathway, the purine metabolism pathway, the
Figure 1. Overview of analysis pipeline.
doi:10.1371/journal.pgen.1002207.g001
Expression Variance and Neurological Disease
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neurotrophin signaling pathway and the cell cycle pathway
(Table 1), each of which has previously been linked to important
aspects of stem cell biology [19–21]. These modules were
significantly different between the cell types tested at the 0.05
level (after adjusting for multiple testing using the Benjamini-
Hochberg method). They were also the most ‘‘representative
pathways,’’ in the sense that they contained the largest numbers of
genes in the list of array probes significant between classes.
Overall we found 21 significant pathways (adjusted P-values
,0.05). However, many of these pathways were overlapping in
their gene content (see Table S1) and together represent three key
common biological themes—immune response, growth factor
signaling, and DNA replication—that are consistent with the
phenotypic differences between the cell types.
In overlaying variance onto these networks we noted that the
numbers of high-variance or highly constrained genes did not
follow the expected population patterns, with a trend towards
more high-variance genes across most of the pathways (Figure 3;
Fig. 7 in Text S1). The purine metabolism and cell cycle pathways
in particular had fewer low-variance and more high-variance
genes than expected (Chi-square goodness of fit P-value ,0.01
and P-value ,1.261026 respectively), an observation consistent in
the hONS and skin fibroblast datasets. In contrast, the
neurotrophin signaling pathway contained far fewer high-variance
genes than expected (Chi-square goodness of fit P-value ,0.01)
suggesting that this network was under greater regulatory
constraint.
Any analysis of variance must consider the contribution of
technical variation to the data. To address this issue we compared
the magnitude of the intra-individual expression variance with the
size of the inter-individual expression variance associated with
each donor group. Four additional donors had each contributed
two independently derived biopsies, resulting in four replicate
samples per donor (see Material and Methods and Text S3). The
intra-individual mean of the CV distribution was smaller than the
inter-individual CV mean, confirming that the technical variation
in this data set was less than the biological variation observed. We
next examined whether this observation held up when controlling
for differences in sample size, by constructing variance distribu-
tions based on the same number of samples (n=4), and found this
trend persisted. Amongst the four individuals, differences in the
CV distributions, albeit slight were observed for the five core
pathway modules. Collectively these results suggest that repeated
sampling of the same individual is associated with less expression
Table 1. The top 21 most discriminating KEGG pathways between the neuronal stem cells obtained from the disease and healthy
control donor groups.
Rank KEGG Pathway ID KEGG Pathway Name Adjusted p-value
Number of Detected
Illumina IDs
1 4010 MAPK signaling pathway 0.01111 235
2 4510 Focal adhesion 0.03578 193
3 230 Purine metabolism 0.02908 143
4 4722 Neurotrophin signaling pathway 0.0003308 137
5 4110 Cell cycle 0.009490 132
6 4012 ErbB signaling pathway 0.001835 94
7 240 Pyrimidine metabolism 0.009490 88
8 4912 GnRH signaling pathway 0.04171 86
9 5220 Chronic myeloid leukemia 0.04171 86
10 5322 Systemic lupus erythematosus 0.0003308 76
11 4210 Apoptosis 0.04171 74
12 5221 Acute myeloid leukemia 0.04171 58
13 480 Glutathione metabolism 0.02949 45
14 3030 DNA replication 0.0003311 36
15 4672 Intestinal immune network for IgA production 0.01143 32
16 3440 Homologous recombination 0.002277 27
17 5332 Graft-versus-host disease 0.04447 27
18 5330 Allograft rejection 0.009490 26
19 5320 Autoimmune thyroid disease 0.03522 26
20 3430 Mismatch repair 0.009490 25
21 5310 Asthma 0.009490 15
All pathways were significant at the 0.05 level (after adjusting for multiple testing using the Benjamini-Hochberg method) and were ranked by the number of detected
probes represented.
doi:10.1371/journal.pgen.1002207.t001
Figure 2. Expression variance is stable under different normalization strategies. A. Assessing the impact of normalization strategies on
genome-wide variance distribution for the hONS stem cells and fibroblasts from the control group. B. Venn diagram demonstrating the geneset
overlap of low-variance (left) or high-variance (right) identified from representative normalization strategies. There was a .75% concordance in the
low-variance groups and a .90% concordance in the high-variance groups.
doi:10.1371/journal.pgen.1002207.g002
Expression Variance and Neurological Disease
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variance, pointing to a strong genetic component in biological
variability.
Disease status alters the variability profiles in core
pathway modules
The distributions of expression variance for each of the patient
groups highlighted an unexpected observation. Using a two
sample t-test on log2 transformed CV values, we saw significant
deviations from the control pattern in the SZ group (P-value
,2.2610216), and also the PD group (P-value ,0.001). This
suggested that the SZ hONS lines demonstrated much less
variation in their genome-wide expression patterns than was
expected and in contrast, the PD hONS lines showed greater
variation in their genome-wide expression patterns (Figure 4A;
Text S2). Applying the same tests to identify disease-specific
differences in genome-wide average expression showed no
significant differences in either donor group.
We then investigated whether the differences in expression
variance observed at a whole genome level were also apparent in
our five core stem cell networks (Table 1). For each of these, we
found that the SZ and PD groups sit at opposite ends of the
variability spectrum (Figure 4C). The SZ group had a marked
reduction in variance signaling pathway, as evidenced by more
highly-constrained genes whereas the PD group had greater
variance than the control group. The deviation in frequency
distributions between the disease group and the control group was
statistically significant for both SZ and PD groups in hONS stem
cells, as assessed by a Chi-squared test with two degrees of
freedom.
One might anticipate that increased expression variance, as
seen in the PD group, is evidence of poor network integrity, a
model that has been suggested as important in complex diseases.
What was surprising, however, is the observation that the SZ
group has significantly reduced expression variability in these core
pathways, suggesting that both extremes of the variability
spectrum may be implicated in disease processes.
These disease-specific patterns were independent on the
particular cut-off used to define the regions of high and low
constraint in the expression variance distribution (Figure 4). When
more stringent cut-offs were applied (e.g. 5% and 10%) the same
general trend of reduced variance for the SZ group and increased
variance for the PD group was still observed.
Highly-constrained and lowly-constrained genes have
different functional roles as reflected by their position in
cellular networks
Disease status was associated with different proportions of lowly-
constrained and highly-constrained genes; this observation raised
the possibility that these two classes may play distinct roles in
maintaining or driving cellular phenotype. Using Gene Ontology
terms (cellular component, molecular function and biological
process categories) [22], we performed a representation analysis
for each set of highly-constrained and lowly-constrained genes in
the pathway modules for the three donor groups. We then mapped
these genes to networks based on highly-annotated protein-protein
interaction data and compared the patterns of transcriptional
constraint between phenotypic states.
We found that genes with high-variance/low constraints were
both functionally and physically involved at the periphery of signal
transduction pathways. In hONS cells, they functioned largely as
cell surface receptors and tended to be localized in the membrane,
transmembrane or extracellular matrix regions (Table S2). This
might suggest that the hONS were heterogeneous for expression of
growth factor receptors and as a population had dynamic
interactions with the extracellular environment. In contrast,
highly-constrained genes tend to function in signaling roles, such
as protein kinases and phosphatases (see Text S4). This might imply
that all of the cells in the hONS population were competent to
transduce signals through the MAPK pathway, and were only
restricted by the expression of receptors or the availability of ligands.
The hONS stem cells derived from SZ donors demonstrated
both loss of variability at the cell surface, and increased constraint
in the intracellular signaling molecules. For MAPK signaling, we
saw significant functional enrichment of signaling GO categories
(Table S2) for low-variance genes in the SZ and control groups,
while there was enrichment for high-variance genes in the PD
group. This suggests that MAPK signaling is particularly
important for distinguishing between these three groups.
Just as cellular distribution of highly-constrained genes was not
random, we observed a nonrandom pattern in the degree-
Figure 3. Distribution of variance patterns in the top 5 attract pathways for hONS and fibroblast cells. Chi-square goodness of fit was
used to determine if variance profiles differed significantly from the expected 25:50:25% patterns.
doi:10.1371/journal.pgen.1002207.g003
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Figure 4. Expression variance discriminates between disease groups. A. Box plots showing whole-genome phenotype-specific mean
expression levels and the corresponding CVs for hONS cells derived from the Control, PD, and SZ patient groups. As can be seen, there is no
difference in the average log2(expression) measures but noticeable differences in the CVs. Using a two-sample t-test, there is a significant difference
between the SZ and Control groups (p-value,2.2610216) and the PD and Control groups (p-value,0.0013). B. The observation of increase in high-
variance genes for PD and increase in low-variance genes for SZ persists with different percentile cutoffs applied to the variance distribution in the
Expression Variance and Neurological Disease
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distribution (connectivity) of genes based on their expression
variance (Figure 5). The lowly-constrained genes had on average, a
low degree whereas the highly-constrained genes were more highly
connected to other genes in the network; this shift from a random
distribution was marginally statistically significant for the control
group (Chi-squared test; P-value = 0.05958 for control group, P-
value = 0.1219 for SZ group, P-value = 0.09595 for PD group,
see Figs. 19 and 20 in Text S1), suggesting that not only are
constraints imposed on genes linked to specific functional roles but
they also have significantly distinct network topologies. Each
disease group was associated with distinct deviations in degree
distributions from those observed for the control group; the degree
distributions between high and low-variance gene sets became
more identical for the SZ group whereas in the PD group, the high
and low-variance distributions appeared reversed from those
observed in the control group. These observations suggest two
Figure 5. MAPK interaction networks and degree distribution density curves for the highly-constrained (red) and lowly-constrained
(green) genes. p-values assess the significance of how different the two degree distributions are. The ‘‘Mid Variability’’ genes, falling between the
25th and 75th percentile of CV values, are shown in gray for comparison.
doi:10.1371/journal.pgen.1002207.g005
MAPK signaling pathway. C. Ratios of gene counts for the attract pathways, showing a trend towards high-variance genes for PD and a significant
increase in low-variance genes for SZ.
doi:10.1371/journal.pgen.1002207.g004
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different vehicles in which normal regulatory control through a
signaling network may be disrupted or perturbed.
In comparing our three patient groups, we observed a consistent
correlation between the degree of a particular gene and its
expression variance, suggesting that transcriptional variability is an
inherent aspect of all cellular systems (Fig. 20 in Text S1). This is
consistent with our intuition that genes that are highly connected,
and therefore play a central role in signaling or other networks,
must be more tightly regulated than those that play more
peripheral roles, including as cell surface receptors and down-
stream effectors.
It may be that the increased expressivity of those genes
peripheral to the network provides a wider range of potential
phenotypic response to external stimuli. In this way, disease
processes that alter the variability in expression of particular genes
may influence phenotype so that reduced expressivity limits the
spectrum of response while increased expressivity tends toward loss
of regulation over the cell’s end-stage response.
Discussion
In genetics, the concepts of expressivity and penetrance describe
phenotype variability between individuals with shared genotypes
and across populations, respectively. The implicit explanations for
phenotypic variability are differences in genetic, epistatic, or
epigenetic interactions. In genomic analysis, we often see this
variability in terms of sequence or structural polymorphisms
within the genome [23] and focus our efforts on understanding the
link between genetic variation and phenotypic diversity. In this
context, low genetic variation leads to poor evolutionary fitness,
whereas the convergence of multiple variants on disease networks
is increasingly thought to contribute to disease states [24,25].
A key element in the central dogma of molecular biology is the
role played by RNA as an intermediary between gene and protein
(and ultimately with phenotype). In this light it is surprising that
variability of expression levels has received so little attention. This
may reflect the fact that in the analysis of gene expression data,
variance is often associated with technical artifacts rather than being
seen as an intrinsic property that reflects the normal range of
phenotypic heterogeneity. If technical noise intrinsic to the platform
was the major driver in variance, then one would expect these
random effects to affect experimental samples equally. Indeed, as
our goal was to do comparisons between phenotypic groups, we
made every effort to minimize experimental noise, beginning with
standardized protocols for sample collection and laboratory
handling, quality control during RNA extraction, and labeling
and hybridization together so as to avoid potential batch effects.
Given that we see specific biases in the variance profiles that
correlate in ameaningful way with phenotype argues that this is not the
case. Our results suggest that this variability is, in fact, a much more
important measure of phenotype than previously recognized and that
changes in the spectrum of expressivity may be fundamentally linked to
the development of distinct phenotypic states.
The expressivity of individual genes such as the pluripotency
factors Oct4 and Nanog has been highlighted by others as an
important contributor to phenotypic robustness of a population of
embryonic stem cells. Variance of gene expression in these cells is
both predictable and essential – providing a dynamic range of
pluripotency factors which is directly linked to the differentiation
potential of individual cells within that population [26,27]. If
expression variance of one or two key regulators is an important
modifier of phenotype, then it holds that this can be measured at a
pathway level as well. Even across cells derived from different
donors, the distribution of expression variance for a pathway is
predictable, and deviations from this correlate with disease
phenotypes. What are the likely sources of this ‘regulated noise’?
The reduced variance observed between hONS lines derived from
different biopsies from the same donor indicates a role for genetics.
One possible scenario is that genetic polymorphism might impose
a combinatorial impact on the expressivity of genes within a
network, and the consequent alteration of dynamic range of that
network outcome. Indeed, the degree of expression variance of a
reporter construct was found to be a heritable trait in S. cerevisiae
[28]. Epigenetic factors are also likely to play a key role in
expressivity at individual loci, and others have shown stochastic,
population-wide variance in epigenetic modification of key
developmental loci. With increasing evidence that expression
variance is an important phenotypic attribute of cell populations, it
holds that variance profiles may also reflect abnormal genetic or
epigenetic events contributing to disease phenotypes.
In this context, it is perhaps not surprising that the most
profound shifts in expression variance were found in hONS cells
isolated from SZ donors. SZ is a life-long psychotic disorder, with
age of onset in males in early adulthood and later in females. SZ is
considered a disease of neurodevelopment, based on epidemio-
logical, histological and genetic evidence [29–32]. It is clear that
SZ is a complex genetic disease with a strong environmental
component. There are several well replicated genome-wide studies
that have implicated common polymorphisms in the etiology of
the disease, although these account for a small component of the
heritability and an emerging theory is that polygenic risks explain
more of the genetic component of this disease. Reduced expression
variance of hONS networks provides fresh clues into potential
mechanisms underlying diseases like SZ. For example, if the
patterns of gene expressivity found in the hONS reflect those
found in the developing brain, then the orderly cascade of brain
development may be altered. In addition, it is feasible that an
overly constrained biological pathway would be less adept at
buffering environmental stressors.
Neuronal stem cells are the progenitors for neural cell states and
the development of brain is rooted in the cell fate decisions that
occur in these stem cells. Olfactory stem cells have been shown to
serve as a good surrogate for neuronal stem cells and stem cell
differentiation[14]. Our analysis of gene expression in olfactory
stem cells cultured from patients with SZ, PD, and matched
controls identified a number of key pathways that distinguished
these three groups, including key signaling and developmental
pathways. What was surprising about these pathways was that not
only was there a notable difference in expression, but that
expressivity, or variability in gene expression levels, was also
significantly different between these different diseases. Further,
when the expressivity was mapped to protein-protein interaction
networks, there were distinctly different patterns of transcriptional
constraint that depended on the connectivity of the proteins in the
network. Further, these patterns depended not only on disease
state, but also on the degree of connectivity within the
corresponding protein-protein interaction pathway.
In examining the network topology, we found that in the SZ
patients, there was significantly greater regulatory control over
genes at the highly-connected core of the corresponding pathways.
For example, in the MAPK pathway, SZ patients exhibited far less
expressivity in the kinases that represent the core of the pathway.
On the other hand, the PD patients had significantly fewer
constrained genes mapping to the same core pathway regions than
did controls. The increased variance associated with some proteins
such as receptors, may indicate that these proteins have fluctuating
turnover rates in the cell populations, which in turn will influence
the capacity of cells to interact with their environment.
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These data, together, paint a very interesting and compelling
picture of the mechanism associated with disease. One of the
defining characteristics of SZ is the disruption of normal cognitive
processes and this is reflected in fewer neural synapses in parts of
the brain. While it is no doubt a leap to interpret our results as
having a direct link to thought processes in the disease, one could
imagine that a high degree of constraint in key transcription factor
networks that play a role in cellular differentiation and
developmental processes. One could imagine that highly con-
strained transcriptional networks in neuronal stem cells could
reduce the spectrum of cellular phenotypes that could be derived
from those stem cells and reduce the plasticity resulting in the
brain and altering its potential responses and thought patterns.
It is worth noting that among the pathways that demonstrate
highly-constrained gene expression in our SZ patients are those
involved in signaling in cancer. One consequence of increased
constraints, and reduced plasticity, is defects in the network are more
likely to be disastrous. In this kind of model, defects in cancer-related
networks would lead to loss of those cells, preventing the types of
adaption observed in cancer development. Although there are
conflicting reports regarding the risk of cancer in schizophrenics, the
majority of reports suggest that patients with SZ are protected against
cancer in general, and from lung and colorectal, despite increased
smoking [33,34] and drinking habits [35] in this population.
Laboratory studies have also reported reduced tumor growth in
animal models of schizophrenia [36]. Although speculative, the high
degree of transcriptional constraint we found in the MAPK pathway
in SZ patients may explain, in part, these observations.
In contrast, disease states may arise where increased variance
changes the predictability of network outcomes, resulting in dysregu-
lation of the desired cell state. In PD, we observed an increase in the
expression variance of core signaling pathways, which we predict will
diminish the robustness of the network to external events. This may be
an essential element that is shared amongst diseases of aging.
Although SZ and PD represent very different conditions, our
results suggest that changes in expressivity relative to the normal
spectrum of variability, may play an important role in the
development of disease phenotypes. One possible way to interpret
this is in the context of models first proposed by Conrad
Waddington [37] and later refined by Stuart Kauffman [38].
Waddington and Kauffman envisioned what we can interpret as a
gene expression state-space landscape defined by possible gene
expression states. In this landscape, stable cell states represent fixed
points (Kauffman referred to these as ‘‘attractors’’) connected by
evolutionarily-defined ‘‘canals’’ representing the differentiation
pathways connecting distinct cell phenotypes. In this model, the
SZ patients would be characterized by more highly-constrained,
‘‘deeper,’’ canals, limiting the potential end states that one might
achieve during differentiation. PD patients, on the other hand,
could be characterized by a flattening of the same canals (what has
been referred to as ‘‘decanalization’’), increasing dysregulation of
the associated pathways and potentially allowing for a degradation
of the well-defined cellular end states that might be available.
While the potential importance of decanalization in disease has
been discussed [25], we believe that our results are the first to
suggest that over-canalization may be an equally important
process in developing disease phenotypes.
Materials and Methods
Ethics statement
This work uses public expression datasets from patient-derived
cells which were collected under the ethics approval of the Griffith
University ethics committee.
Gene expression data set
Illumina Human-Refseq8 v2 BeadChips (Illumina, Inc.) arrays
were used to capture genome-wide gene expression profiles; the
raw data was summarized using BeadStudio Version 3.1.7(Illu-
mina, Inc). Background correction and normalization methods
were performed using the R/Bioconductor lumi package. All
downstream analyses were performed using Quantile normalized
data, without background correction, and only probes passing the
Illumina detection threshold were included in variance analysis. A
probes was considered to pass the Illumina detection score if it had
a detection p-value #0.01 in at least 75% of individuals in the
same donor group, resulting in 14,986 probes. This expression
data is available from ArrayExpress under the experiment
accession number E-TABM-724.
Intra-individual variance
Illumina Human-Refseq8 v3 BeadChips (Illumina, Inc.) arrays
were used to collect genome-wide gene expression profiles of the
four replicate samples for each of the four donors. The donors
were made up of two healthy controls and two PD patients, and
each donor underwent two independently derived biopsies that
were each replicated twice, giving rise to four samples per donor.
The raw gene expression data set was summarized as above. The
data set was filtered using the same detection filter, and the subset
of 6,809 detected probes common to the v3 and v2 arrays was used
for the comparison of intra-individual and inter-individual
variance analysis. To gauge the effect of sample size on variance,
the inter-individual variance was calculated by computing CV
distributions based on a random subset of 4 individuals from each
donor group, and comparing these to the intra-individual CV
distributions that were calculated from the four samples for each
individual. From the 100 random subsets generated, we observed a
reduction in the difference between the inter-individual variance
and the intra-individual variance when the sample size was
reduced and fixed at four replicates.
Attract method
The attract package can be obtained from Bioconductor [http://
www. bioconductor.org/packages/devel/bioc/html/attract.html] and
is available as a module in the MeV microarray analysis software [39]
(http://www.tm4.org/mev). To identify activated core pathways
whose expression defines a control hONS phenotype, we ran attract
on an expression data set consisting of the skin fibroblasts and two types
of hONS lines from the control patients and a set of mesenchymal stem
cell lines from a group of unrelated individuals. Attract was run using
pathway modules defined by KEGG pathways represented in
Bioconductor (version 2.4.1, Biobase version 2.8.0 and illuminaHu-
manv2BeadID.db version 1.6.0).
Identifying low- and high-expression variance genes
A CV value was calculated for each detected probe by dividing
the standard deviation of its expression in a donor group by its
average group expression. Low and high-expression variance
genes were identified as those genes below and above the 25th
percentile of the genome-wide CV distribution based on values
from all donors.
Assessing the significance of disease status versus
healthy control group
P-values were obtained by comparing the counts of high,
medium and low constraint genes in each of the control, SZ and
PD groups and using a Chi-squared goodness of fit test where
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counts from the control group were designated as the expected
counts.
Representational analysis
For each of the top five pathway modules, we applied a
representational analysis to the set of highly-constrained and
lowly-constrained genes for each of the donor groups. We used
tools from the Bioconductor GOstats package (version 2.14.0, run
on R version 2.11.1). P-values were adjusted for using the
Benjamini-Hochberg method within each ontology class, donor
group and pathway module (Cellular Component, Molecular
Function, or Biological Process) and significant results obtained at
the 0.05 level. To focus on what functional terms were unique to
genes of altered constraint, we excluded significant GO terms that
appeared in both lists of highly-constrained and lowly-constrained
genes and retained only those GO terms that were unique to each
list. The significant GO terms for highly-constrained genes appear
in the Supplementary File.
Network topology p-values
A Kolmogorov-Smirnov test was used to test the degree
distributions of the lowly and highly-constrained gene sets. A
Gaussian kernel density estimator (the density function from R,
using the default method to select bandwidth size) was used to
produce the degree distribution density plots shown in Figure 4.
Literature-curated networks
Protein-protein interactions were defined using two knowledge-
based annotation systems, Ingenuity Pathway Analysis (IPA)
software and the GeneGo metacore tool. Both tools permitted
identification of highly curated protein-protein interactions; using
IPA we extracted the degree of connectivity for each gene in the
attract-networks and an image of the interaction network was
obtained from GeneGo.
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Table S2 Functional enrichment (GO) tables.
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of different normalization methodologies on variance distributions
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